GT Biopharma, Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 22 May 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 26 Nov 2025 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Past financial statements no longer reliable (8-K Item 4.02)
The company stated in a Form 8-K (Item 4.02) filed on 02 Mar 2026 that previously issued financial statements should no longer be relied upon. This usually leads to a restatement of past results.
More details →GT Biopharma, Inc. — Overview & Financial Snapshot
GT Biopharma, Inc. (NasdaqCM: GTBP) is a Healthcare company, ranked #3,708 of 6,774 companies globally and #1,669 of 4,000 in United States on PositoAI, with a Positivity Score of 20,303. Its market capitalisation is ₹107.39 Cr ($11.38M), P/E ratio is -0.0 and P/B ratio is 1.50. It currently has 2 active red flags (PosiRed) and 1 yellow flag (PosiYellow, 6/10 points) on record.
For financial statements, ratio trends and score history, Go Deep →